Cybin Inc. Reports Strong Shareholder Participation in 2025 Annual Meeting
Cybin Inc. announced robust shareholder engagement with nearly 49% of outstanding shares represented at its annual meeting, demonstrating significant investor confidence in the company's late-stage neuropsychiatry treatments for major depressive disorder and generalized anxiety disorder.
